Regenerative Medicine News

NeoStem: The Best Upside In An Innovating Space
Seeking Alpha
With only one approved product that has a cell therapy as its main component, the potential for new treatments and the outlook for those treatments is at an all-time high. The valuation for companies in this space is particularly attractive, perhaps ...
See all stories on this topic »​